Pancreatic Cancer: New Nerve-Targeting Therapies & Research Breakthroughs
- Pancreatic cancer, notoriously difficult to diagnose early and often resistant to conventional treatments, is increasingly understood to have a complex relationship with the nervous system.
- For years, clinicians have observed what’s known as perineural invasion, where cancer cells migrate within nerves, using them as pathways to metastasize.
- The research, published in scientific journals and highlighted by SciTechDaily and ScienceDaily, shows that specialized support cells within the pancreas, called myCAFs, release chemical signals that actively attract...
Pancreatic cancer, notoriously difficult to diagnose early and often resistant to conventional treatments, is increasingly understood to have a complex relationship with the nervous system. Recent research is revealing that nerves aren’t simply involved in the spread of pancreatic cancer – they actively fuel its growth from the very beginning, presenting a potential new target for therapies.
For years, clinicians have observed what’s known as perineural invasion, where cancer cells migrate within nerves, using them as pathways to metastasize. However, investigations led by researchers at the Cold Spring Harbor Laboratory (CSHL) and detailed in findings released on , demonstrate that the nervous system’s involvement begins much earlier in the disease process. “In other words cancer cells will migrate within the nerve and use the nerve as a way to metastasize,” explains Jeremy Nigri, a postdoctoral researcher in Professor David Tuveson’s lab at CSHL.
The research, published in scientific journals and highlighted by SciTechDaily and ScienceDaily, shows that specialized support cells within the pancreas, called myCAFs, release chemical signals that actively attract nearby nerve fibers. These nerves then release signals that accelerate early cancer growth, creating a self-sustaining loop that helps tumors establish themselves.
This discovery builds on a growing understanding of how stress signals can fundamentally alter tissue behavior during both inflammation and cancer. Researchers have observed that these signals essentially “switch on” fibroblasts, transforming them into myCAFs, which then actively recruit nerves into the pancreas. This process isn’t a passive consequence of the tumor’s presence; it’s an active recruitment of the nervous system to support cancer development.
The implications of this finding are significant. Experiments detailed in the CSHL research demonstrate that blocking nerve activity significantly reduced tumor growth. This suggests that interrupting the communication between the nerves and the cancer cells could be a viable therapeutic strategy. Recent work, published in Nature, further explores this concept, detailing the development of nanodrugs designed to specifically target this nerve-cancer crosstalk.
The Nature study focuses on using bacterial-derived outer membrane vesicles conjugated with a nerve-binding peptide, loaded with a tropomyosin receptor kinase (Trk) inhibitor. This targeted approach aims to disrupt the neurotrophin/Trk signaling pathway, effectively diminishing nerve growth and reducing the proliferation and migration of pancreatic cancer cells. The researchers also found that this approach can repolarize tumor-associated macrophages, further enhancing the nerve intervention and augmenting the effectiveness of chemotherapy like gemcitabine.
The research doesn’t stop at simply understanding the mechanism. Scientists are actively working on translating these findings into tangible treatments. One promising avenue involves targeting the HPDL enzyme, which plays a crucial role in the production of CoQ10, a molecule that fuels tumor growth. Research from New York University Langone Health, as reported by Damon Runyon on , has even led to a medical intervention for a rare neurological disease caused by HPDL deficiencies, demonstrating the broader potential of this research.
While these findings offer a hopeful outlook, it’s important to remember that this research is ongoing. The nanodrugs described in the Nature study, for example, are still under investigation, and larger clinical trials are needed to confirm their efficacy and safety. Similarly, the treatment developed for the neurological disease requires further study to fully understand its long-term effects.
Pancreatic cancer remains a formidable challenge, but the growing understanding of its interaction with the nervous system is opening up new avenues for treatment. By targeting the communication pathways between nerves and cancer cells, researchers are hopeful that they can develop more effective therapies to combat this devastating disease. The focus is shifting from simply treating the tumor to disrupting the very environment that allows it to thrive.